Fas、Bcl—2在肾癌中表达的研究

目的：检测Fas,Bcl-2在肾癌中的表达，分析其在肾癌发生发展中的作用。方法：采用免疫组化法，结果：1．肾癌Fas比正常肾组织阳性表达率低，Bcl-2比正常肾组织高（P＜0．05），2．Fas,Bcl-2表达在肾癌的细胞学分类，病理分级，临床分期无显著性差异（P＞0．05），3．肾癌Fas表达与Bcl-2负相关（P＜0．05，r=-0.322),4.单因素生存分析Fas,Bcl-2表达及肾癌的各细胞学分类生存率无差异（P＞0．05），肾癌病理分级G1＋G2组比G3＋G4组生存率高（P＜0．05），临床分期S1＋S2组比S3＋S4组高（P＜0．05），Cox回归多因素生存分析只发现肾癌病理分级能单儿作为反映肾癌预后因素的指标（P＜0．05）。结论：Fas，Bcl-2在肾癌的发生中并不能单独起主导作用。不能独立作为反映肾癌预后的指标，它们可能只是参与肾癌发生多种因素之一。

Study of Fas and Bcl-2 in renal cell carcinoma

Objective To detect the expression of Fas, Bcl-2 in renal cell carcinoma (RCC).Methods Fifty-three specimens of RCC and 22 specimens of normal renal tissue were detected by immunohistochemistry.Results\ Fas revealed weaker expressions on the surface of renal cancer cells than renal cells,while Bcl-2 revealed stronger expressions(P<0.05). Fas immmunoactivity negatively correlated with Bcl-2 expression (P<0.05,r=-0 322). During univariate analysis,the survival rates of Fas, Bcl-2 positive cases and their negative cases were not different(P>0.05);the survival rates of grade 1 grade 2 cases and stage 1 stage 2 cases were higher than those of grade 3 grade 4 cases and stage 3 stage 4 cases respectively(P<0.05). During multivariate analysis,only the histological grade could become an independent prognosticator for survival(P<0.05). Conclusion Fas,Bcl-2 could not serve as only marker in the evaluation of the malignancy and prognosis of RCC.